Skip to search formSkip to main contentSkip to account menu

STX209

Known as: STX-209 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Arbaclofen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A MEG Study of Acute Arbaclofen (STX-209) Administration
Several electrophysiological parameters, including the auditory evoked response component M50/M100 latencies and the phase… 
2017
2017
Nonmedical use of prescription drugs in adolescents and young adults: not just a Western phenomenon
onists have been tested in ASD associated with fragile X syndrome, and showed promise in a subgroup of patients. GABAergic agents… 
2014
2014
Baseline characteristics influencing placebo response in clinical trials of treatments for fragile X syndrome
Fragile X Syndrome (FXS) is a disorder caused by a congenital mutation of the FMR1 gene on the X chromosome. FXS is associated… 
Review
2013
Review
2013
Pain: morphine, metabolites, mambas, and mutations
2012
2012
Trialing targeted therapies for autism
study identified a complete loss of synaptic retinoic acid signaling and associated homeostatic plasticity in FXS mice 5 . It is… 
Review
2011
Review
2011
ACS chemical neuroscience molecule spotlight on STX209 (arbaclofen).
STX209 (arbaclofen) is a γ-amino butyric acid type B (GABA(B)) receptor agonist from Seaside Therapeutics currently in clinical… 
2011
2011
Effects of STX209 (arbaclofen) on Social and Communicative Function in Autism Spectrum Disorder: Results of an 8-Week Open-Label Trial
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)